Revolution Medicines gets FDA nod for targeted pancreatic cancer drug

FDA approved Revolution Medicines’ targeted therapy for adults with metastatic pancreatic cancer who have had prior treatment or cannot receive combination chemotherapy. The approval is a meaningful regulatory milestone that can expand the company’s addressable opportunity in a high-unmet-need oncology setting.